References
Hallett WA, Maguire RP, McCarthy TJ, Schmidt ME, Young H (2007) Considerations for generic oncology FDG-PET/CT protocol preparation in drug development. IDrugs 10(11):791–796, Nov
Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE (2008) Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26(13):2155–2161, Epub 2008 Mar 24, May 1
Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF, Postmus PE, Teule GJJ, Lammertsma AA (2000) Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 27:731–743
Kinahan P, Christian P, Karp J, Chaitanya D, Zubal G, Pappas V, McEwan A (2007) A calibration phantom for multi-center PET/CT studies of assessing response to therapy. J Nucl Med 48(Supplement 2):194P
Kinahan P, Doot R, Christian P, Karp J, Scheuermann J, Zimmerman R, Saffer J, McEwan A (2008) Multi-center comparison of a PET/CT calibration phantom for imaging trials. J Nucl Med 49(Supplement 1):63P
Minn H, Zasadny KR, Quint LE, Wahl RL (1995) Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-D-glucose uptake at PET. Radiology 196:167–173
Weber WA, Ziegler SI, Thodtmann R, Hanauske A, Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771–1777
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Frank, R. Quantitative Imaging Biomarkers Alliance FDG–PET/CT Working Group Report. Mol Imaging Biol 10, 305 (2008). https://doi.org/10.1007/s11307-008-0167-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-008-0167-y